Journal of cardiology cases | 2021

Complete remission from post-heart transplant lymphoproliferative disorder: A case report.

 
 
 
 
 
 
 

Abstract


We report a case of Burkitt s lymphoma, post-transplant lymphoproliferative disorder (BL-PTLD) that was treated with intensive chemotherapy. The patient was a 4-year-old boy who underwent heart transplantation at 7 months of age for refractory heart failure due to dilated cardiomyopathy. He was admitted to our hospital with a chief complaint of abdominal pain associated with an abdominal mass. Computed tomography was notable for a bulky mass arising from the terminal ileum. Fluorodeoxyglucose-positron emission tomography revealed multiple lesions in brain, bone, and lymph nodes. He was diagnosed with BL-PTLD stage III by pathological and clinical scoring. He was Epstein-Barr virus (EBV)-seronegative with a low EBV viral DNA load. No EBV-encoded small RNAs were in his intra-abdominal lymph nodes by in situ hybridization. On cytogenetic examination, the intra-abdominal lymph nodes revealed both a MYC rearrangement and a t(8;14)(q24;32), t(16;19)(q24;q13.1) translocation. Administration of tacrolimus and mycophenolate mofetil was discontinued; immunosuppression was maintained with everolimus. Intensive chemotherapy based on the modified LMB 96 protocol for BL was initiated, resulting in complete remission achieved. During the intensive chemotherapy and immunosuppressive switching period, cardiac dysfunction and allograft rejection had not been shown. The patient has remained well for two years after the treatment with no evidence of relapse. <Learning objective: Post-transplant lymphoproliferative disorder (PTLD) is a life-threatening complication that can develop after heart transplantation and result in significant morbidity and mortality. In the case presented here, intensive chemotherapy and modified immunosuppressive therapy are among the most effective treatments for PTLD patients with an otherwise poor prognosis. Maintaining a fine balance between management of the PTLD and preventing allograft rejection is critically important.>.

Volume 24 2
Pages \n 60-63\n
DOI 10.1016/J.JCCASE.2020.12.010
Language English
Journal Journal of cardiology cases

Full Text